1. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective Clin Exp Rheumatol 2001;19:6 Suppl 25. S15-S22.
2. Bijlsma JW, Van Everdingen AA, Huisman M, De Nijs RN, Jacobs JW. Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann N Y Acad Sci 2002;966:82-90.
3. Conaghan PG, Brooks P. Disease - modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D - penicillamine. Curr Opin Rheumatol 1996;8:176-182.
4. Breedveld FC, Dijkmans BAC. Differential therapy in early and late stages of rheumatoid arthritis. Curr Opin Rheumatol 1996;8:226-229.
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-911.
6. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Gall E, et al. Methotrexate in rheumatoid arthritis; a five year prospective multicenter study. Arthritis Rheum 1994;37:1492-1498.
7. Sharp JT, Strand V, Leung H, Hurley F, Loew-Fiedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum 2000;43:495-505.
8. Pisetsky DS, St Clair EW. Progress in the treatment of rheumatoid arthritis. JAMA 2001;286:2787-2790.
9. Marra CA, Esdaile JM, Guh D, Fisher JH, Chalmers A, Anis AH. The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis Rheum 2001;45:240-245.
10. Criscione LG, St Clair EW. Tumor necrosis factor - alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-211.
11. Patel DD. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum 2002;46:1984-1985.
12. Furst DE. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 2002;14:220-224.